ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

(2017) Yi-Long Wu et al.   LANCET ONCOLOGY

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

(2017) Michaël Duruisseaux et al.   Oncotarget

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erlotinib and bevacizumabversuscisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer

(2015) Michael Thomas et al.   EUROPEAN RESPIRATORY JOURNAL

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

(2015) Meghan Shea et al.   Therapeutic Advances in Respiratory Disease

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer

(2013) Gerold Bepler et al.   JOURNAL OF CLINICAL ONCOLOGY

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer

(2013) Luc Friboulet et al.   NEW ENGLAND JOURNAL OF MEDICINE

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

(2013) S Postel-Vinay et al.   ONCOGENE

Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients

(2012) C. M. Choi et al.   ANNALS OF ONCOLOGY

Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses

(2012) W. E. Pierceall et al.   ANNALS OF ONCOLOGY

Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2011) Joshua A. Roth et al.   Clinical Lung Cancer

Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations

(2011) Richard A. Hubner et al.   PLoS One

High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients

(2010) Shengxiang Ren et al.   CANCER INVESTIGATION

Different Impact of Excision Repair Cross-Complementation Group 1 on Survival in Male and Female Patients With Inoperable Non–Small-Cell Lung Cancer Treated With Carboplatin and Gemcitabine

(2009) Bente Holm et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy

(2009) Hyun Woo Lee et al.   LUNG CANCER